ROCO
4172
Market cap53mUSD
Nov 12, Last price
17.70TWD
Name
Innopharmax Inc
Chart & Performance
P/E
—
P/S
51.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.20%
Rev. gr., 5y
-17.57%
Revenues
32m
-29.90%
Net income
-99m
L+40.18%
CFO
-76m
L+56.93%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson's disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation. The company was founded in 1994 and is based in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||